Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)

This observational study is collecting real-world data on how patients with acute myeloid leukemia (AML) respond to newer approved drugs — such as gilteritinib, IDH inhibitors, oral azacytidine, glasdegib, and gemtuzumab ozogamicin — when used outside of controlled clinical trials, in everyday practice. **You may be eligible if...** - You are 18 or older and have been diagnosed with AML (excluding the APL subtype) - You are being treated with one of the newer approved AML drugs (listed above) in standard clinical practice - You have signed informed consent (where required by your institution) **You may NOT be eligible if...** - You are already enrolled in an interventional (experimental treatment) clinical trial - You have APL (M3 AML subtype) Talk to your doctor to see if this trial is right for you.